{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:53:22Z","timestamp":1789210402623,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T00:00:00Z","timestamp":1476489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Endotis Pharma, Romainville, France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00228-016-2143-9","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T19:10:39Z","timestamp":1476472239000},"page":"15-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neutralization of EP217609, a new dual-action FIIa\/FXa anticoagulant, by its specific antidote avidin: a phase I study"],"prefix":"10.1007","volume":"73","author":[{"given":"P.","family":"Gueret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Krezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fuseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L. M.","family":"van Giersbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Petitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Neuhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,15]]},"reference":[{"issue":"10","key":"2143_CR1","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2011-09-381764","volume":"119","author":"ST Olson","year":"2012","unstructured":"Olson ST, Swanson R, Petitou M (2012) Specificity and selectivity profile of EP217609: a new, neutralizable, dual-action anticoagulant that targets thrombin and factor Xa. Blood 119(10):2187\u20132195","journal-title":"Blood"},{"key":"2143_CR2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1160\/TH09-01-0063","volume":"102","author":"M Petitou","year":"2009","unstructured":"Petitou M, Nancy-Portebois V, Dubreucq G, Motte V, Meuleman D, de Kort M, van Boeckel CAA, Vogel GMT, Wisse JAJ (2009) From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 102:804\u2013810","journal-title":"Thromb Haemost"},{"key":"2143_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2077-2","author":"P Gueret","year":"2016","unstructured":"Gueret P, Combe S, Krezel C, Fuseau E, van Giersbergen PL, Petitou M, Neuhart E (2016) First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action. Eur J Clin Pharmacol. doi: 10.1007\/s00228-016-2077-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"2143_CR4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1537-2995.2008.01666.x","volume":"48","author":"SA Snyder-Ramos","year":"2008","unstructured":"Snyder-Ramos SA, M\u00f6hnle P, Weng YS, B\u00f6ttiger BW, Kulier A, Levin J, Mangano DT, Investigators of the Multicenter Study of Perioperative Ischemia; MCSPI Research Group (2008) The ongoing variability in blood transfusion practices in cardiac surgery. Transfusion 48(7):1284\u20131299","journal-title":"Transfusion"},{"key":"2143_CR5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11239-008-0280-4","volume":"26","author":"M Yavari","year":"2008","unstructured":"Yavari M, Becker RC (2008) Anticoagulant therapy during cardiopulmonary bypass. J Thromb Thrombolysis 26:218\u2013228","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2143_CR6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1089253207311154","volume":"11","author":"AF Merry","year":"2007","unstructured":"Merry AF (2007) Focus on thrombin: alternative anticoagulants. Semin Cardiothorac Vasc Anesth 11(4):256\u2013260","journal-title":"Semin Cardiothorac Vasc Anesth"},{"issue":"3","key":"2143_CR7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtcvs.2005.10.049","volume":"131","author":"NG Smedira","year":"2006","unstructured":"Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL 2nd, Lincoff AM, Spiess BD, Aronson S (2006) Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131(3):686\u2013692","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2143_CR8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","volume":"131","author":"CM Dyke","year":"2006","unstructured":"Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL 2nd, Kirshner R, Lincoff AM, Spiess BD (2006) A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131(3):533\u2013539","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2143_CR9","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00134-004-2388-0","volume":"30","author":"D Paparella","year":"2004","unstructured":"Paparella D, Brister SJ, Buchanan MR (2004) Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 30:1873\u20131881","journal-title":"Intensive Care Med"},{"issue":"3","key":"2143_CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jtcvs.2009.02.021","volume":"138","author":"MC Christensen","year":"2009","unstructured":"Christensen MC, Krapf S, Kempel A, von Heymann C (2009) Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 138(3):687\u2013693","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"2143_CR11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0029-1185915","volume":"57","author":"JF Gummert","year":"2009","unstructured":"Gummert JF, Funkat A, Beckmann A, Schiller W, Hekmat K, Ernst M, Haverich A (2009) Cardiac surgery in Germany during 2008. A report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 57(6):315\u2013323","journal-title":"Thorac Cardiovasc Surg"},{"key":"2143_CR12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0971-9784.38444","volume":"11","author":"BH Scott","year":"2008","unstructured":"Scott BH, Seifert FC, Grimson R (2008) Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth 11:15\u201319","journal-title":"Ann Card Anaesth"},{"issue":"6","key":"2143_CR13","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.athoracsur.2008.01.053","volume":"85","author":"PP Brown","year":"2008","unstructured":"Brown PP, Kugelmass AD, Cohen DJ, Reynolds MR, Culler SD, Dee AD, Simon AW (2008) The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg 85(6):1980\u20131986","journal-title":"Ann Thorac Surg"},{"issue":"22","key":"2143_CR14","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.698977","volume":"116","author":"GJ Murphy","year":"2007","unstructured":"Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD (2007) Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 116(22):2544\u20132552","journal-title":"Circulation"},{"issue":"2","key":"2143_CR15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0971-9784.41591","volume":"11","author":"R Juneja","year":"2008","unstructured":"Juneja R, Mehta Y (2008) Blood transfusion is associated with increased resource utilisation, morbidity, and mortality in cardiac surgery. Ann Card Anaesth 11(2):136\u2013137","journal-title":"Ann Card Anaesth"},{"key":"2143_CR16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1010-7940(99)00134-7","volume":"16","author":"SAM Nashef","year":"1999","unstructured":"Nashef SAM, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R, the EuroSCORE study group (1999) European system for cardiac operative risk evaluation (EuroSCORE). Eur J Card Thor Surg 16:9\u201313","journal-title":"Eur J Card Thor Surg"},{"issue":"5","key":"2143_CR17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0049-3848(97)00082-0","volume":"86","author":"B P\u00f6tzsch","year":"1997","unstructured":"P\u00f6tzsch B, Hund S, Madlener K, Unkrig C, M\u00fcller-Berghaus G (1997) Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 86(5):373\u2013383","journal-title":"Thromb Res"},{"issue":"1","key":"2143_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","volume":"33","author":"HC Hemker","year":"2003","unstructured":"Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, B\u00e9guin S (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33(1):4\u201315","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"5","key":"2143_CR19","first-page":"553","volume":"96","author":"HC Hemker","year":"2006","unstructured":"Hemker HC, Al Dieri R, De Smedt E, B\u00e9guin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96(5):553\u2013561","journal-title":"Thromb Haemost"},{"issue":"4","key":"2143_CR20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000081505","volume":"33","author":"G Nowak","year":"2003","unstructured":"Nowak G (2003) The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33(4):173\u2013183","journal-title":"Pathophysiol Haemost Thromb"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2143-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2143-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2143-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T12:33:32Z","timestamp":1568464412000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2143-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["2143"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2143-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,15]]}}}